过氧化物酶体增殖物激活受体γ对皮肤生理功能和病理过程的影响

doi:10.35541/cjd.20200947

Abstract

Abstract: 【Abstract】 Peroxisome proliferator-activated receptors （PPARs） are widely involved in lipid metabolism, glucose metabolism, cell growth and differentiation, and inflammation in the human body. PPARγ agonists can inhibit skin inflammatory response, protect epidermal barrier function, and repair skin injury. This review summarizes various roles of PPARγ in skin biology, and discusses its function in skin diseases, such as psoriasis and skin tumors.

Key words: Peroxisome proliferator-activated receptors, Inflammation, Wounds and injuries, Skin aging, Skin neoplasms, Psoriasis

Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes[J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.doi:10.35541/cjd.20200947

References ［31］

［1］	Zhou F, Teng X, Wang P, et al. Isolation, identification, expression and subcellular localization of PPARG gene in buffalo mammary gland［J］. Gene, 2020,759:144981. doi: 10. 1016/j.gene.2020.144981.
［2］	Chang JS, Ha K. A truncated PPAR gamma 2 localizes to mitochondria and regulates mitochondrial respiration in brown adipocytes［J/OL］. PLoS One, 2018,13（3）:e0195007（2018⁃03⁃22）［2021⁃12⁃07］. https://journals.plos.org/plosone/article?id=10. 1371/journal.pone.0195007. doi: 10. 1371/journal.pone.0195007.
［3］	Ramot Y, Bertolini M, Boboljova M, et al. PPAR⁃γ signalling as a key mediator of human hair follicle physiology and pathology［J］. Exp Dermatol, 2020,29（3）:312⁃321. doi: 10.1111/exd.14062.
［4］	Bastien M, Poirier P, Brassard P, et al. Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: a 1⁃yr randomized study［J］. Am J Physiol Endocrinol Metab, 2019,317（1）:E65⁃65E73. doi: 10.1152/ajpendo.00505.2018.
［5］	Liefke R, Bokelmann K, Ghadimi BM, et al. Enhancer⁃driven transcriptional regulation is a potential key determinant for human visceral and subcutaneous adipocytes［J］. Biochim Biophys Acta Gene Regul Mech, 2018. doi: 10.1016/j.bbagrm.2018.06. 007.
［6］	Ramot Y, Bertolini M, Boboljova M, et al. PPAR⁃γ signalling as a key mediator of human hair follicle physiology and pathology［J］. Exp Dermatol, 2020,29（3）:312⁃321. doi: 10.1111/exd.14062.
［7］	Guo W, Han J, Wu S, et al. Bis（2⁃ethylhexyl）⁃2,3,4,5⁃tetrabromophthalate affects lipid metabolism in zebrafish larvae via DNA methylation modification［J］. Environ Sci Technol, 2020,54（1）:355⁃363. doi: 10.1021/acs.est.9b05796.
［8］	da Rocha G, de Paula⁃Silva M, Broering MF, et al. Pioglitazone⁃mediated attenuation of experimental colitis relies on cleaving of annexin A1 released by macrophages［J］. Front Pharmacol, 2020,11:591561. doi: 10.3389/fphar.2020.591561.
［9］	Maślanka T, Otrocka⁃Domagała I, Zuśka⁃Prot M, et al. Beneficial effects of rosiglitazone, a peroxisome proliferator⁃activated receptor⁃γ agonist, in a mouse allergic asthma model is not associated with the recruitment or generation of Foxp3⁃expressing CD4（+） regulatory T cells［J］. Eur J Pharmacol, 2019,848:30⁃38. doi: 10.1016/j.ejphar.2019.01.053.
［10］	Mao X, Liu L, Cheng L, et al. Adhesive nanoparticles with inflammation regulation for promoting skin flap regeneration［J］. J Control Release, 2019,297:91⁃101. doi: 10.1016/j.jconrel.2019. 01.031.
［11］	Pascual G, Fong AL, Ogawa S, et al. A SUMOylation⁃dependent pathway mediates transrepression of inflammatory response genes by PPAR⁃gamma［J］. Nature, 2005,437（7059）:759⁃763. doi: 10.1038/nature03988.
［12］	Kanemaru M, Asai J, Jo JI, et al. Nanoparticle⁃mediated local delivery of pioglitazone attenuates bleomycin⁃induced skin fibrosis［J］. J Dermatol Sci, 2019,93（1）:41⁃49. doi: 10.1016/j.jdermsci.2018.11.012.
［13］	Flori E, Mastrofrancesco A, Kovacs D, et al. The activation of PPARγ by 2,4,6⁃Octatrienoic acid protects human keratinocytes from UVR⁃induced damages［J］. Sci Rep, 2017,7（1）:9241. doi: 10.1038/s41598⁃017⁃09578⁃3.
［14］	Yang CC, Wu CH, Lin TC, et al. Inhibitory effect of PPARγ on NLRP3 inflammasome activation［J］. Theranostics, 2021,11（5）:2424⁃2441. doi: 10.7150/thno.46873.
［15］	Sahu RP, DaSilva SC, Rashid B, et al. Mice lacking epidermal PPARγ exhibit a marked augmentation in photocarcinogenesis associated with increased UVB⁃induced apoptosis, inflammation and barrier dysfunction［J］. Int J Cancer, 2012,131（7）:E1055⁃1066. doi: 10.1002/ijc.27562.
［16］	Dai X, Sayama K, Shirakata Y, et al. STAT5a/PPARgamma pathway regulates involucrin expression in keratinocyte differentiation［J］. J Invest Dermatol, 2007,127（7）:1728⁃1735. doi: 10.1038/sj.jid.5700758.
［17］	Yang R, Chowdhury S, Choudhary V, et al. Keratinocyte aquaporin⁃3 expression induced by histone deacetylase inhibitors is mediated in part by peroxisome proliferator⁃activated receptors （PPARs）［J］. Exp Dermatol, 2020,29（4）:380⁃386. doi: 10.1111/exd.14080.
［18］	García⁃Martín A, Garrido⁃Rodríguez M, Navarrete C, et al. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis［J］. Biochem Pharmacol, 2019,163:321⁃334. doi: 10.1016/j.bcp.2019.02.029.
［19］	Park HJ, Park HS, Lee JU, et al. Sex⁃based selectivity of PPARγ regulation in Th1, Th2, and Th17 differentiation［J］. Int J Mol Sci, 2016,17（8）. doi: 10.3390/ijms17081347.
［20］	Xin X, Yang S, Kowalski J, et al. Peroxisome proliferator⁃activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo［J］. J Biol Chem, 1999,274（13）:9116⁃9121. doi: 10.1074/jbc.274.13.9116.
［21］	Westergaard M, Henningsen J, Johansen C, et al. Expression and localization of peroxisome proliferator⁃activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin［J］. J Invest Dermatol, 2003,121（5）:1104⁃1117. doi: 10.1046/j.1523⁃1747.2003.12536.x.
［22］	US FDA says withdraw troglitazone［J］. Reactions Weekly, 2000,795（1）:2. doi: 10.2165/00128415⁃200007950⁃00004.
［23］	Ramot Y, Mastrofrancesco A, Camera E, et al. The role of PPARγ⁃mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology［J］. Exp Dermatol, 2015,24（4）:245⁃251. doi: 10.1111/exd.12647.
［24］	Peng Y, Zhang Q, Zielinski RM, et al. Identification of an irreversible PPARγ antagonist with potent anticancer activity［J］. Pharmacol Res Perspect, 2020,8（6）:e00693. doi: 10.1002/prp2.693.
［25］	Ren L, Konger RL. Evidence that peroxisome proliferator⁃activated receptor γ suppresses squamous carcinogenesis through anti⁃inflammatory signaling and regulation of the immune response［J］. Mol Carcinog, 2019,58（9）:1589⁃1601. doi: 10.1002/mc.23041.
［26］	Kotlinowski J, Jozkowicz A. PPAR gamma and angiogenesis: endothelial cells perspective［J］. J Diabetes Res, 2016,2016:8492353. doi: 10.1155/2016/8492353.
［27］	Kim JK, Mun S, Kim MS, et al. 5,7⁃Dimethoxyflavone, an activator of PPARα/γ, inhibits UVB⁃induced MMP expression in human skin fibroblast cells［J］. Exp Dermatol, 2012,21（3）:211⁃216. doi: 10.1111/j.1600⁃0625.2011.01435.x.
［28］	Shen D, Li H, Zhou R, et al. Pioglitazone attenuates aging⁃related disorders in aged apolipoprotein E deficient mice［J］. Exp Gerontol, 2018,102:101⁃108. doi: 10.1016/j.exger.2017.12. 002.
［29］	Das RN, Balupillai A, David E, et al. Naringin, a natural flavonoid, modulates UVB radiation⁃induced DNA damage and photoaging by modulating NER repair and MMPS expression in mouse embryonic fibroblast cells［J］. J Environ Pathol Toxicol Oncol, 2020,39（2）:191⁃199. doi: 10.1615/JEnvironPatholToxicol Oncol.2020031914.
［30］	Chen L, Bi B, Zeng J, et al. Rosiglitazone ameliorates senescence⁃like phenotypes in a cellular photoaging model［J］. J Dermatol Sci, 2015,77（3）:173⁃181. doi: 10.1016/j.jdermsci.2015.01.007.
［31］	Briganti S, Flori E, Bellei B, et al. Modulation of PPARγ provides new insights in a stress induced premature senescence model［J］. PLoS One, 2014,9（8）:e104045. doi: 10.1371/journal.pone.0104045.

[1]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[2]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[3]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[4]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[5]	Liu Lu, Yin Cuiyuan, Hu Hongzhong, He Linlin, . Collagen peptide against chronological skin aging: mechanisms of action and related clinical studies [J]. Chinese Journal of Dermatology, 2023, 56(5): 455-458.
[6]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[7]	Yue Chao, Duan Mengying, Wang Tao, Zhang Manyu, Dai Yeqin, Peng Jianzhong, Song Xiuzu. Application of the upper eyelid orbicularis oculi myocutaneous island flap in repairing secondary defects after resection of eyelid and periorbital skin tumors: a retrospective analysis of 28 cases [J]. Chinese Journal of Dermatology, 2023, 0(4): 20220013-e20220013.
[8]	Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360.
[9]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210794-e20210794.
[10]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[11]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[12]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[13]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[14]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[15]	Huang He, Zhang Xuejun. Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 181-184.

Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［31］

Related Articles 15

Metrics

Comments

Recommended 10